Model for End-Stage Liver Disease-Based Organ Allocation: Managing the Exceptions to the Rules

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 5, 2013, Pages 452-453

  Goldberg, David S ^a   Fallon, Michael B ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; END STAGE LIVER DISEASE; GRAFT RECIPIENT; HEPATOPULMONARY SYNDROME; HUMAN; LIVER CELL CARCINOMA; PEER REVIEW; PORTOPULMONARY HYPERTENSION; PRIMARY SCLEROSING CHOLANGITIS; TUMOR GROWTH; UNITED STATES;

END STAGE LIVER DISEASE; HUMANS; ORGAN TRANSPLANTATION; TISSUE AND ORGAN PROCUREMENT; WAITING LISTS;

EID: 84876721488     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.02.014     Document Type: Editorial

References (24)

1. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
2. Wiesner R., Edwards E., Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003, 124:91-96.
3. Freeman R.B., Gish R.G., Harper A., et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006, 12(Suppl 3):S128-S136.
4. Gores G.J., Gish R.G., Shrestha R., et al. Model for end-stage liver disease (MELD) exception for bacterial cholangitis. Liver Transpl 2006, 12(Suppl 3):S91-S92.
5. Cucchetti A., Cescon M., Bigonzi E., et al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011, 17:1344-1354.
6. Accessed January 2, 2013. http://www.unos.org/docs/RRB_Public_FAQ.pdf.
7. Thuluvath P.J., Guidinger M.K., Fung J.J., et al. Liver transplantation in the United States, 19992008. Am J Transplant 2010, 10:1003-1019.
8. According to OPTN/UNOS data available as of March 31, 2011, as provided in a UNOS STAR file.
9. Bittermann T., Makar G., Goldberg D. Exception point applications for 15 points: an unintended consequence of the Share 15 policy. Liver Transpl 2012, 18:1302-1309.
10. Goldberg D., Bittermann T., Makar G. Lack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis. Am J Transplant 2012, 12:1603-1609.
11. Goldberg D., French B., Abt P., et al. Increasing disparity in waitlist mortality rates with increased MELD scores for candidates with versus without hepatocellular carcinoma. Liver Transpl 2012, 18:434-443.
12. Massie A.B., Caffo B., Gentry S.E., et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 2011, 11:2362-2371.
13. Policy 3.6: allocation of livers Organ Procurement and Transplantation Network, Accessed February 4, 2013. http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf.
14. Washburn K., Edwards E., Harper A., et al. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010, 10:1643-1648.
15. Arguedas M.R., Abrams G.A., Krowka M.J., et al. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003, 37:192-197.
16. Fallon M.B., Krowka M.J., Brown R.S., et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008, 135:1168-1175.
17. Schenk P., Schöniger-Hekele M., Fuhrmann V., et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003, 125:1042-1052.
18. Swanson K.L., Wiesner R.H., Krowka M.J. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005, 41:1122-1129.
19. Sulieman B.M., Hunsicker L.G., Katz D.A., et al. OPTN policy regarding prioritization of patients with hepatopulmonary syndrome: does it provide equitable organ allocation?. Am J Transplant 2008, 8:954-964.
20. Krowka M.J., Fallon M.B., Mulligan D.C., et al. Model for End-Stage Liver Disease (MELD) exception for portopulmonary hypertension. Liver Transpl 2006, 12:S114-S116.
21. Ashfaq M., Chinnakotla S., Rogers L., et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007, 7:1258-1264.
22. Fix O.K., Bass N.M., De Marco T., et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007, 13:875-885.
23. Sussman N., Kaza V., Barshes N., et al. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant 2006, 6:2177-2182.
24. Organ procurement and transplantation: assessing current policies and the potential impact of the DHHS final rule 1999, Institute of Medicine, Institute of Medicine, Washington, DC.